Lilly Taltz (ixekizumab) Phase 3 trial reaches primary and secondary ends
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Lilly(http://announced that its IL-17A inhibitor Taltz (ixekizumab) had reached the main end and all critical secondary endpoints in theoftest (http://treating patients with severe plaque psoriasis between the ages of 6 and 18About Taltz
Taltz is an IL-17A monoclonal antibody developed by LillyIL-17A is an inflammatory cytokineBy combining with IL-17A, Taltz can reduce inflammation levels, which can relieve symptoms in patientsbefore that, Taltz had been approved by theFDA(http://for the treatment of psoriasis and psoriasis arthritis (PsA)A total of 201 patients with moderate to severe plaque psoriasis under the age of 6 to 18 were involved in a 3-stage clinical study in the randomized, double-blind, placebo-controlled groupresults showed that in week 12, the proportion of patients treated with Taltz with a reduction of more than 75% (PASI 75) was significantly higher than in the control group, at 89% and 25%, respectivelyFurthermore, 81 percent of patients in the treatment group met a complete or near-clear edified (PGA 0,1) score for skin symptoms, compared with 11 percent of patients in the placebo group who reached the primary endpoint of the trialin addition,have reached critical secondary endpoints, including PASI 90, PASI 100, sPGA 0, and exponential improvements measured by itch NRS
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
